Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-996-9058
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable
Myomo (NASDAQ:MYO) Frequently Asked Questions
What is Myomo's stock symbol?
Myomo trades on the NASDAQ under the ticker symbol "MYO."
How were Myomo's earnings last quarter?
Myomo, Inc. (NASDAQ:MYO) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.02. The firm had revenue of $0.88 million for the quarter, compared to analysts' expectations of $1.09 million. View Myomo's Earnings History.
When is Myomo's next earnings date?
What is the consensus analysts' recommendation for Myomo?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myomo.
Has Myomo been receiving favorable news coverage?
News stories about MYO stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Myomo earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Myomo.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Electromed (ELMD), Protech Home Medical (PHM), Oventus Medical (OVN), Resonance Health (RHT), Osprey Medical (OSP), Universal Biosensors (UBI), GI Dynamics (GID), EMvision Medical Devices (EMV), Avacta Group (AVCT), LBT Innovations (LBT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Anteo Diagnostics (ADO), Azure Healthcare (AZV) and Aurora Spine (ASG).
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 63)
- Ms. Davie Mendelsohn RN, VP of Sales & Clinical Services (Age 64)
- Mr. Jonathan Naft, VP & GM (Age 53)
- Mr. Ralph A. Goldwasser, Chief Financial Officer (Age 70)
- Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 68)
How do I buy shares of Myomo?
Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of MYO stock can currently be purchased for approximately $0.7708.
How big of a company is Myomo?
What is Myomo's official website?
How can I contact Myomo?
The company can be reached via phone at 617-996-9058.
MarketBeat Community Rating for Myomo (NASDAQ MYO)
MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe MYO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days.
